RxDoctor Payments Data

Christopher Konstantelos, MD

Internal Medicine · Chicago, ILNPI 1952330243

Payments from drug & device makers

$2,217in general payments, 2019–2025

Across 44 payments — averaging $50.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$815
  • Viiv Healthcare Company$721
  • Gilead$550
  • Johnson & Johnson$49
  • Biotronik NRO, Inc.$42
  • Novo Nordisk$24
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,92787%
  • Education$29013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,217 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$49,776
Medicare patients
110
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala100$498,937
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf82$429,984
TivicayDolutegravir Sodium110$323,090
DescovyEmtricitabine/Tenofov Alafenam115$290,403
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$99,446
JardianceEmpagliflozin35$56,130
OzempicSemaglutide41$47,196
EliquisApixaban41$41,420
PrezcobixDarunavir/Cobicistat12$32,096
MounjaroTirzepatide20$22,791
EdurantRilpivirine Hcl13$22,075
TrulicityDulaglutide20$21,118
EvotazAtazanavir Sulfate/Cobicistat12$19,266
Maraviroc13$16,473
FarxigaDapagliflozin Propanediol14$12,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$550$888,785230 claims
Janssen Products, LPSymtuza$815$429,98482 claims
Viiv Healthcare CompanyTivicay$721$323,090110 claims
Novo NordiskOzempic$24$47,19641 claims
Lilly USA, LLCMounjaro, Trulicity$16$43,91040 claims
Johnson & JohnsonPrezcobix$49$32,09612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →